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Hepatitis E virus (HEV) infection is increasingly recognized as a cause of acute hepatitis
in the industrialized world. We aimed to determine the frequency of acute HEV infection
in cases of suspected drug-induced liver injury (DILI), mainly a diagnosis of exclusion.
To this aim, formalin-fixed paraffin-embedded (FFPE) liver tissues of all cases routinely
processed in our institute during a 2 1/2 years period in which DILI was among the differ-
ential diagnoses (157 liver biopsies, 1 liver explant) were subjected to semi-nested RT-PCR
for the detection of HEV RNA. Histopathology was re-evaluated on all cases tested posi-
tive. HEV RNA was detectable in 3 of 158 cases (2%) tested, comprising autochthonic as
well as travel-related infections with genotypes 1, 3, and 4 each found once, respectively.
Histopathologic findings comprised one case with subtotal hepatic necrosis and two cases
of acute (cholestatic) hepatitis not distinguishable from acute hepatitis of other etiology.
Thus, the overall frequency of acute HEV infection as determined by detection of HEV RNA
in liver tissue is substantially increased in patients with suspected DILI compared to the
healthy population, emphasizing the need to actively look for HEV infection in cases of
suspected DILI. Molecular testing for HEV RNA in routinely processed FFPE liver tissues
can be applied to cases with undetermined HEV status.
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INTRODUCTION
Hepatitis E virus (HEV) has long been known to cause epidemic
infection leading to acute liver disease mostly in the developing
world without affecting industrialized countries. However, more
recent data have established increased rates of autochthonous
infection in some European countries (1, 2) with the infection
considered to be zoonotic and food-borne instead of waterborne
as in developing countries (3, 4). HEV RNA is reported to be
detectable in <0.1% of the healthy population in industrialized
countries, e.g., in 0.037% of blood donors in the Netherlands (5)
and 0.08% of blood donors in Germany (6), although seropreva-
lence might be much higher (5, 7). Symptomatic infection with
HEV can cause acute liver disease indistinguishable from hepatitis
A and might even be the more common infectious agent caus-
ing acute hepatitis (3, 8, 9). Still, testing for HEV in cases of acute
hepatitis is not done on a regular basis, due in part to uncertainties
in the consistency of serological assays based on the detection of
HEV-specific antibodies (7, 10).
Drug-induced liver injury (DILI) is a diagnosis of exclusion and
recent studies have shown high incidences in industrialized coun-
tries (11, 12). DILI presents with a wide spectrum of histological
patterns including changes mimicking acute hepatitis (13), and in
the absence of conclusive testing for HEV, might mask underlying
hepatic injury primarily due to infection with HEV. Indeed, HEV
infection has been documented in cases of suspected DILI sero-
logically via detection of viral RNA in serum (14, 15) as well as
in liver tissue from hepatitis cases of clinically unexplained origin
(16). This study was designed to determine the presence of HEV
infection in liver tissue and its frequency in cases in which DILI
was among the differential diagnoses.
MATERIALS AND METHODS
PATIENT SAMPLES AND STUDY DESIGN
One hundred and fifty seven liver biopsies and one liver explant
obtained from individual patients at the University Hospital
Zurich, Switzerland during 2011, 2012, and first half of 2013
were retrospectively included in our study. All patients had a sus-
pected DILI based on either clinical and/or histological findings.
Patients with previous liver transplantation were excluded from
the study. This retrospective study was reviewed and approved by
the internal review board of the University Hospital Zurich and the
Cantonal Ethics Committee of Zurich, Switzerland (KEK-ZH-Nr.
2013-0504).
RNA EXTRACTION, RT-PCR, AND SEQUENCING
RNA from formalin-fixed paraffin-embedded (FFPE) tissue was
isolated using Trizol® LS (Life Technologies). In brief, FFPE tis-
sue was cut, incubated in 0.02M Tris/0.02 EDTA/1% SDS at 95°C
for 10 min, centrifuged at 4°C, and solid paraffin removed. Tis-
sue was digested with proteinase K (55°C for 48–72 h), Trizol LS
added to the solution, and homogenized using shredding columns
(Qiagen). After addition of chloroform, the flow-through was
further subjected to centrifugation and the aqueous upper part
removed to precipitate total RNA with 2-propanol. One micro-
gram of total RNA was reverse transcribed (iScript™ cDNA syn-
thesis kit, Bio-Rad) and resulting cDNA tested for the presence of
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HEV using a semi-nested PCR approach targeting a HEV-specific
gene region. Oligo nucleotide primers for first round amplifi-
cation were: F: 5-TCGGGTGGAATGAATAACATGT-3 and R1:
5-GGTTGGTTGGATGAATATAAGGGG -3 resulting in a 232 bp
amplicon. Oligo nucleotide primers for second round amplifi-
cation were: F: 5-TCGGGTGGAATGAATAACATGT-3 and R2:
5-CGGTCACCCCAGAAACCAC-3 resulting in a 185 bp ampli-
con. Oligo nucleotide primer sequences are based on a whole-
genome alignment of 165 HEV-strains and conserved regions
therein corresponding to nucleotides of HEV reference sequence
HQ634346.1: F: nt 5135-5156, R1: nt 5366-5388; R2: nt5319-5301,
respectively.
RT-PCR for β-actin and a second housekeeping gene (GAPDH)
by real time RT-PCR was performed for all samples analyzed. PCR
products were sequenced by direct Sanger sequencing to confirm
specificity of the amplicon. Sequences were aligned to publicly
accessible HEV reference sequences to determine HEV genotype
using the BLAST program (http://www.ncbi.nlm.nih.gov).
The detection of HEV RNA was confirmed by parallel or ret-
rospective serum testing in the Swiss reference laboratory for
HEV testing (Prof. Darius Moradpour, Gastroenterology and
Hepatology Division, CHUV, Lausanne).
HISTOLOGY
Histological evaluation as provided by initial surgical pathological
report was recorded including extent of inflammation, fibrosis,
cholestasis, steatosis, and architectural alterations. Histological
reevaluation was performed on all HEV RNA positive cases.
RESULTS
CHARACTERISTICS OF PATIENTS WITH SUSPECTED DRUG-INDUCED
LIVER INJURY
In total, 157 cases in which DILI was among the differential diag-
noses and patients underwent liver biopsy and 1 liver explant from
a patient with suspected DILI from January 2011 through June
2013 were identified and liver tissue specimen analyzed for the
presence of HEV RNA. Histological features of necroinflamma-
tory activity and fibrosis according to the classification of Batts
and Ludwig (17), steatosis and cholestasis as well as gender and age
of patients are summarized in Table 1. Female and male patients
were equally distributed in this cohort (females: 51%, males: 49%)
and more than half belonged to the group of patients 30–60 years
of age (Table 1). No specific medication appeared to be dispropor-
tionally frequently taken, except for amoxicillin/clavulanic acid (5
cases) and azathioprine (3 cases), instead no other single medica-
tion was implicated in more than one case and medication covered
a wide range of drugs (data not shown). Necroinflammatory activ-
ity was mostly present (absent in only 4%) and varying degrees of
fibrosis were common (67%). Cholestasis was noted in one-third
of cases, mostly canalicular (21%) or hepatocellular (11%) and the
majority of cases had absence of steatosis (59%).
DETECTION OF VIRAL RNA IN LIVER TISSUES
An initial comparison of already established (18) and newly
designed primer sets targeting well conserved viral sequences in
three different semi-nested RT-PCR assays (data not shown) led
to the identification of the most reliable protocol (oligos F, R1,
Table 1 | Characteristics of study patients with suspected
drug-induced liver injury.
N (%)
Female 81 (51.3)
Age (years)
<30 22 (13.9)
30–60 91 (57.6)
>60 45 (28.5)
Necroinflammatory activity
Grade 0 6 (3.8)
Grade 1 58 (36.7)
Grade 2 71 (44.9)
Grade 3 20 (12.7)
Grade 4 3 (1.9)
Fibrosis
Grade 0 53 (33.5)
Grade 1 58 (36.7)
Grade 2 20 (12.7)
Grade 3 18 (11.4)
Grade 4 9 (5.7)
Cholestasis
Hepatocellular 18 (11.4)
Canalicular 33 (20.9)
Ductal 5 (3.2)
Absent 102 (64.6)
and R2, see above). Using this protocol throughout the study, the
overall frequency of HEV RNA detection in our study cohort was
2% (3/158). However, limitations inherent to RNA detection in
FFPE were found when repetitive or parallel testing of individual
cases was performed. HEV RNA was detectable in only 3 out of 4
different paraffin blocks of the hepatectomy specimen from case
number 1 that presented with fulminant acute hepatitis and later
underwent liver transplantation. Furthermore, case number 3 was
tested positive in only 2 out of 6 runs. In contrast, case number 2
was always tested positive. Also, quality testing of RNA/cDNA with
β-actin as an internal control gave positive results in only 151 out
of 155 negative cases and analysis of a second housekeeping gene
(GAPDH) via real time RT-PCR showed amplification mostly in
late cycles (>30 cycles, Figures S1A–C in Supplementary Material
and data not shown). Sequencing of positive cases confirmed the
specificity of the amplification (Figures S1D–F in Supplementary
Material).
CLINICO-PATHOLOGICAL FEATURES OF HEV RNA POSITIVE CASES
Travel-associated HEV infection (genotype 1) was found in case
number 1. This non-pregnant, 26 years old female patient reported
traveling to India with one episode of fever (39°C) and recur-
rent epigastric pain during her stay. The epigastric pain persisted
after her return and she developed emesis and nausea as well
as generalized icterus shortly before hospitalization. Liver trans-
plantation was performed due to fulminant liver failure. In the
initial histopathological report of the explanted liver (Figure 1A
for macroscopy and histology), the differential diagnoses of either
an underlying infectious or toxic (drug-induced) etiology were
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FIGURE 1 | (Histo)-pathological findings of cases tested positive for HEV
RNA. (A) Case 1: macroscopy of liver explant (left picture, bar represents
1 cm), subtotal necrosis (low magnification, middle micrograph, scale bar:
2 mm), and lobular inflammation with confluent necrosis (high magnification,
right micrograph, scale bar: 50µm). (B) Case 2: pronounced
necro-inflammatory activity (H&E and silver reticulin stain, left and middle
micrograph, respectively, scale bar: 100µm). Moderate portal and lobular
inflammation with spotty necrosis (arrow; right micrograph, scale bar 50µm).
(C) Case 3: mild inflammation (H&E, silver reticulin stain and sirius red, from
left to right, scale bar: 50µm).
discussed. However, testing for HEV RNA in autologous liver tis-
sue (this study) and serum was positive. Already 1 week after liver
transplantation, serum was negative for HEV RNA by RT-PCR.
No further biopsy was taken afterward.
Case number 2 had a liver biopsy (Figure 1B) due to presen-
tation with otherwise unexplained icterus for 2 weeks and ele-
vated transaminases but low immunoglobulins. Acute cholestatic
hepatitis was confirmed histologically (Figure 1B) with suspected
toxic (drug-induced) liver injury and retrospectively, HEV RNA
was detected in the liver biopsy (genotype 3).
In case number 3, liver failure with icterus and cholesta-
tic hepatitis was reported clinically due to suspected DILI after
intake of statins, however, intake was stopped 2 weeks before pre-
sentation. Autoimmune markers were negative and total serum
immunoglobulin was not elevated. This patient also reported trav-
eling to Corsica (mediterranean sea) 1 month before falling sick.
The patient had a protracted clinical course with reconvalescence
only after 9 months. HEV RNA (genotype 4) was retrospectively
detected in liver tissue (this study) and also in stored serum taken
during acute illness. Liver histology of case number 3 is shown in
Figure 1C.
None of the three study patients revealed significant liver fibro-
sis. A summary of characteristics of HEV RNA positive cases
including detailed histological findings is presented in Table 2.
DISCUSSION
In this study on a cohort of 158 patients, we found HEV RNA
with a frequency of 2% in liver tissues from patients in which
DILI was among the differential diagnoses. Compared to findings
based on sera testing for HEV RNA, this rate is remarkably simi-
lar to data from an US American study, in which HEV RNA was
detected in 4 out of 318 (1.3%) sera from patients with suspected
DILI (15), but lower compared to a smaller British DILI cohort
in which 6 out of 28 patients (21%) with criterion-referenced
DILI had autochthonous HEV infection (14). In a recent report,
real time RT-PCR performed on RNA extracted from liver tis-
sue in cases of acute hepatitis of clinically unexplained origin,
7 out of 221 cases examined were positive for HEV and 4 out
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Table 2 | Characteristics of HEV RNA positive cases.
Case # Case No. 1 Case No. 2 Case No. 3
Age 26 36 59
Sex F M M
HEV genotype 1 3 4
HEV RNA in serum Positive Not available Positive
Traveled to India 1 month before
presentation; acute liver failure
(ALT>8000 U/l, AST>5000 U/l)
Autochthonous infection with no
travel history; icteric, elevated
aminotransferases (>5×ULN)
Statin intake stopped 2 weeks before
presentation icteric, cholestatic
hepatitis (ALT 550 U/l, AST 170 U/l)
Interface hepatitis (0–4) 2 3 1
Lobular inflammation (0–4) 3 2 1
Portal inflammation (0–4) 3 3 1
Focal necrosis (0–4) 4 1 1
Confluent necrosis (0–6) 6 0 0
Hepatocyte rosettes Yes No No
Lobular disarray Yes Yes Yes
Plasma cells Yes Yes Yes
Eosinophils None Few Few
Neutrophils Isolated None None
Fibrosis stage (0–6) 0 0 0
Cholestasis grade (0–3) 3 1 2
Hepatocellular cholestasis Yes Yes Yes
Canalicular cholestasis No No Yes
Ductal cholestasis No No No
Ductal paucity
None x x x
Mild
Moderate to marked
Ductal reaction No Mild Moderate
of these 7 positive cases were sequenced as being genotype 3
HEV (16). Taken into account that not all HEV-positive cases of
our study cohort were consistently tested positive in repetitive
or parallel testing – performed due to limited RNA-quality –
it is conceivable that the actual rate of HEV infection in DILI
cases might even be higher. Taken together, accumulating evi-
dence from our and similar studies points to an underestimated
role of HEV infection in industrialized countries as the culprit
for acute hepatitis other than drug-induced or otherwise virally
precipitated.
In line with a previous report (19), pathological analysis of
the cases of this study did not reveal any histopathological find-
ings specific or even highly characteristic for HEV infection,
which could be helpful for differential diagnosis against DILI-
related changes. Therefore, we suggest testing for HEV RNA
in cases of suspected DILI, which is also possible on liver tis-
sue as reported here and by others (16). RT-PCR for HEV
can be expected to be the more reliable method when com-
pared to antibody-based serological testing in which false positive
as well as false negative results are a major concern (7, 10).
However, we would like to caution that the quality of cDNA
obtained from RNA isolated from paraffin-embedded liver tis-
sue is crucial, but sometimes limited and might therefore lead to
false negative results. Therefore, optimization of protocols that
increase the quality of RNA extracted from FFPE liver tissue is
needed.
Taken together, we, here, report for the first time the detection
of HEV infection directly from liver tissue in a substantial cohort of
patients with suspected DILI. In line with previous data based on
sera testing (14, 15), we find an increased frequency of HEV RNA
in patients with suspected DILI. Since histopathological findings
of HEV are overlapping with patterns found in DILI, we suggested
performing HEV testing in all cases of suspected DILI which is
also possible from FFPE liver tissues.
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